Erythropoiesis: insights into pathophysiology and treatments in 2017
A Zivot, JM Lipton, A Narla, L Blanc - Molecular Medicine, 2018 - Springer
Erythropoiesis is a tightly-regulated and complex process originating in the bone marrow
from a multipotent stem cell and terminating in a mature, enucleated erythrocyte. Altered red …
from a multipotent stem cell and terminating in a mature, enucleated erythrocyte. Altered red …
Impact of inflammation on myeloproliferative neoplasm symptom development
HL Geyer, AC Dueck, RM Scherber… - Mediators of …, 2015 - Wiley Online Library
Myeloproliferative neoplasms (essential thrombocythemia, ET; polycythemia vera, PV;
myelofibrosis, MF) are monoclonal malignancies associated with genomic instability …
myelofibrosis, MF) are monoclonal malignancies associated with genomic instability …
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms
Protein acetylation is an important contributor to cancer initiation. Histone deacetylase 6
(HDAC6) controls JAK2 translation and protein stability and has been implicated in JAK2 …
(HDAC6) controls JAK2 translation and protein stability and has been implicated in JAK2 …
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) …
G Barosi, A Tefferi, C Besses, G Birgegard, F Cervantes… - Leukemia, 2015 - nature.com
The discovery of somatic mutations, primarily JAK2V617F and CALR, in classic BCR-ABL1-
negative myeloproliferative neoplasms (MPNs) has generated interest in the development of …
negative myeloproliferative neoplasms (MPNs) has generated interest in the development of …
The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms
V Skov, CH Riley, M Thomassen, L Kjær… - Leukemia & …, 2017 - Taylor & Francis
Gene expression profiling in Philadelphia-negative chronic myeloproliferative neoplasms
(MPNs) have unraveled significant deregulation of several immune and inflammation genes …
(MPNs) have unraveled significant deregulation of several immune and inflammation genes …
Metabolic vulnerabilities and epigenetic dysregulation in myeloproliferative neoplasms
V Sharma, KL Wright, PK Epling-Burnette… - Frontiers in …, 2020 - frontiersin.org
The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are associated with
clonal myelopoiesis, elevated risk of death due to thrombotic complications, and …
clonal myelopoiesis, elevated risk of death due to thrombotic complications, and …
Epigenetic diversity in hematopoietic neoplasms
Tumor cell populations display a remarkable extent of variability in non-genetic
characteristics such as DNA methylation, histone modification patterns, and differentiation …
characteristics such as DNA methylation, histone modification patterns, and differentiation …
Novel therapies for myelofibrosis
K Pettit, O Odenike - Current hematologic malignancy reports, 2017 - Springer
Abstract Purpose of Review The purpose of the review was to provide a contemporary
update of novel agents and targets under investigation in myelofibrosis in the Janus kinase …
update of novel agents and targets under investigation in myelofibrosis in the Janus kinase …
Emerging drugs for the treatment of myelofibrosis
A Shreenivas, J Mascarenhas - Expert Opinion on Emerging Drugs, 2018 - Taylor & Francis
Introduction: Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative
neoplasm (MPN). It can be sub-categorized into primary myelofibrosis, post polycythemia …
neoplasm (MPN). It can be sub-categorized into primary myelofibrosis, post polycythemia …
Chromatin dynamics at the core of kidney fibrosis
B Tampe, M Zeisberg - Matrix Biology, 2018 - Elsevier
Progression of chronic kidney disease is a principal challenge in Nephrology, as effective
therapies to halt or even reverse established lesion are not available yet. While numerous …
therapies to halt or even reverse established lesion are not available yet. While numerous …